Darya Chudova is the Chief Technology Officer at Guardant Health Inc., a leading precision oncology company focused on developing blood tests for the early detection of cancer. With a strong background in molecular biology and bioinformatics, Chudova has been instrumental in driving the technological advancements at Guardant Health. She holds a Ph.D. in Molecular Biology from the University of California, Berkeley, and has over two decades of experience in the field of genomics and oncology. Before joining Guardant Health, Chudova held various leadership positions in the biotechnology industry. She worked at Veracyte, where she led the development of genomic diagnostic tests for cancer, and at Affymetrix, where she contributed to the development of microarray technology for gene expression analysis. Her expertise in translating complex genomic data into clinically actionable insights has been pivotal in the success of Guardant Health's liquid biopsy platform, which has revolutionized cancer detection and monitoring. As the CTO of Guardant Health, Chudova oversees the company's technology strategy and innovation pipeline. She leads a team of scientists and engineers in developing and refining the company's proprietary digital sequencing technology, which enables the detection of cancer-related genetic mutations from a simple blood draw. Under her leadership, Guardant Health has launched several groundbreaking products, including the Guardant360 test for advanced cancer patients and the Shield test for early colorectal cancer detection. Chudova's visionary approach and commitment to improving patient outcomes have solidified Guardant Health's position as a leader in the field of precision oncology.